lobbying_activities: 1413039

Individual lobbying activities reported in quarterly filings. Each row is one issue area for one client — includes the specific issues lobbied on, government entities contacted, and income/expense amounts.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

This data as json

id	filing_uuid	filing_type	registrant_name	registrant_id	client_name	filing_year	filing_period	issue_code	specific_issues	government_entities	income_amount	expense_amount	is_no_activity	is_termination	received_date
1413039	d17ef4c1-f56f-4466-a326-779369b71083	Q2	RED+BLUE STRATEGIES	400693064	PEW CHARITABLE TRUSTS	2013	second_quarter	PHA	Issues related to continuing to increase the supply of new and innovative antibiotics that will help to treat the myriad antibiotic resistant strains of bugs like MRSA.H.R. 933 - Consolidation and Further Continuing Appropriations Act of 2013 - Focused on funding for the FDA, CDC and other public health related industries. H.R. 2186 - VALID Compounding Act - Focused on increasing safety for compounded drugs S. 959 - Pharmaceutical Compounding Quality and Accountability Act - Focused on compounding and continued work on issues related to downstream supply chain safety of prescription medications Continued work on issues related to downstream supply chain safety of prescription medications	Executive Office of the President (EOP),HOUSE OF REPRESENTATIVES,SENATE	30000		0	0	2013-07-18T14:02:41.137000-04:00